0000000000669722

AUTHOR

B Ritchie

showing 2 related works from this author

Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

2017

Prevenció; Atac d'angioedema; Inhibidor C1 Prevención; Ataque de angioedema; Inhibidor C1 Prevention; Angioedema attack; C1 inhibitor BACKGROUND: Hereditary angioedema is a disabling, potentially fatal condition caused by deficiency (type I) or dysfunction (type II) of the C1 inhibitor protein. In a phase 2 trial, the use of CSL830, a nanofiltered C1 inhibitor preparation that is suitable for subcutaneous injection, resulted in functional levels of C1 inhibitor activity that would be expected to provide effective prophylaxis of attacks. METHODS: We conducted an international, prospective, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase 3 trial to evaluate the …

Male:aminoácidos péptidos y proteínas::péptidos::serpinas::proteínas inactivadoras del complemento C1::proteína inhibidora del complemento C1 [COMPUESTOS QUÍMICOS Y DROGAS]0301 basic medicine:Otros calificadores::Otros calificadores::/prevención & control [Otros calificadores]Enzims proteolítics - InhibidorsSelf AdministrationSeverity of Illness Indexlaw.inventionC1-inhibitorSubcutaneous injection0302 clinical medicineRandomized controlled triallawCross-Over StudiesHereditary Angioedema Types I and IIbiologyEdema - PrevencióGeneral Medicine:Cardiovascular Diseases::Vascular Diseases::Angioedema::Angioedemas Hereditary [DISEASES]AnesthesiaHereditary angioedema:Other subheadings::Other subheadings::/administration & dosage [Other subheadings]Female:Amino Acids Peptides and Proteins::Peptides::Serpins::Complement C1 Inactivator Proteins::Complement C1 Inhibitor Protein [CHEMICALS AND DRUGS]medicine.symptomComplement C1 Inhibitor Protein:enfermedades cardiovasculares::enfermedades vasculares::angioedema::angioedemas hereditarios [ENFERMEDADES]AdultRiskmedicine.medical_specialtyInjections Subcutaneous:Aminoácidos Péptidos y Proteínas::Péptidos::Serpinas::Proteínas Inactivadoras del Complemento 1::Proteína Inhibidora del Complemento C1 [COMPUESTOS QUÍMICOS Y DROGAS]Placebo:Other subheadings::Other subheadings::/prevention & control [Other subheadings]03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumans:Therapeutics::Drug Therapy::Drug Administration Routes::Injections::Injections Subcutaneous [ANALYTICAL DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT]:Otros calificadores::Otros calificadores::/administración & dosificación [Otros calificadores]Dose-Response Relationship DrugAngioedemabusiness.industry:Terapéutica::Tratamiento Farmacológico::Vías de Administración de Medicamentos::Inyecciones::Inyecciones Subcutáneas [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]Injeccions hipodèrmiquesmedicine.diseaseCrossover studyClinical trial:terapéutica::farmacoterapia::vías de administración de medicamentos::inyecciones::inyecciones subcutáneas [TÉCNICAS Y EQUIPOS ANALÍTICOS DIAGNÓSTICOS Y TERAPÉUTICOS]030104 developmental biology030228 respiratory systembiology.proteinbusinessNew England Journal of Medicine
researchProduct

Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism

2013

BackgroundWhether the oral factor Xa inhibitor edoxaban can be an alternative to warfarin in patients with venous thromboembolism is unclear. MethodsIn a randomized, double-blind, noninferiority study, we randomly assigned patients with acute venous thromboembolism, who had initially received heparin, to receive edoxaban at a dose of 60 mg once daily, or 30 mg once daily (e.g., in the case of patients with creatinine clearance of 30 to 50 ml per minute or a body weight below 60 kg), or to receive warfarin. Patients received the study drug for 3 to 12 months. The primary efficacy outcome was recurrent symptomatic venous thromboembolism. The principal safety outcome was major or clinically re…

MESH: Pulmonary EmbolismMale[SDV]Life Sciences [q-bio]Kaplan-Meier Estimate030204 cardiovascular system & hematologylaw.inventionMESH: Venous Thromboembolismchemistry.chemical_compound0302 clinical medicineRandomized controlled trialEdoxabanlawMESH: Double-Blind Method030212 general & internal medicineMESH: WarfarinMESH: AgedMESH: Middle AgedHazard ratioGeneral MedicineVenous ThromboembolismMiddle AgedThrombosis3. Good healthPulmonary embolismAnesthesiaFemaleAnticoagulants EdoxabanMESH: HemorrhageAndexanet alfamedicine.drugMESH: EnoxaparinHemorrhageMESH: AnticoagulantsMESH: Drug Administration ScheduleDrug Administration Schedule03 medical and health sciencesDouble-Blind MethodAged; Anticoagulants; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Hemorrhage; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pulmonary Embolism; Venous Thromboembolism; WarfarinmedicineHumansEnoxaparinAdverse effectMESH: Kaplan-Meier EstimateAgedMESH: Humansbusiness.industryWarfarinAnticoagulantsmedicine.diseaseMESH: MalechemistryWarfarinbusinessPulmonary EmbolismMESH: FemaleNew England Journal of Medicine
researchProduct